Skip to main content

Table 1 Novel autoantibodies of potential diagnostic relevance in rheumatoid arthritis

From: Autoantibodies in rheumatoid arthritis and their clinical significance

Antibody (year) Antigen (year) Sensitivity (%) Specificity (%) References
Antikeratin (1979) Filaggrin (1993) 40 92–99 [49]
  Anticitrullinated peptides (1998) = deiminated arginine identified in filaggrin (1999) and in fibrin (2001) 53* 96 [8, 1013]
Anti-RA33 (1989) hnRNP-A2 (1992) 32 90–96 [6, 1421]
Anti-Sa (1994) 50 kDa protein, unidentified 42 98 [11, 20, 22, 23]
Anti-p68 (1995) BiP/grp78 (2001) 40 96 [24, 25]
  1. BiP, immunoglobulin binding protein; grp78, glucose-regulated protein 78 kDa; hnRNP-A2, heterogeneous nuclear ribonucleoprotein A2. * In rheumatoid factor-negative patients, approximately 15%. Specificity of anti-RA33 when a diagnosis of systemic lupus erythematosus (SLE) or mixed connective tissue disease (MCTD) can be excluded, or in the absence of autoantibodies associated with SLE or MCTD (anti-DNA, anti-Sm, anti-U1 RNP, anti-Ro, anti-La).